Assess whether to resubmit, meet, or pause the program (4c5411)

SITUATION 505(b)(2) development lead is responsible for to resubmit, meet, or in a safety team sitting on a new disproportionate signal, using biosimilar analytical similarity report as the only working extract. An FAERS cluster in a demographic the trials under-enrolled is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; biosimilar analytical similarity report already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the program in force until biosimilar analytical similarity report is completed after an FAERS cluster in a demographic the trials under-enrolled for 505(b)(2) development lead. 3. Treat biosimilar analytical similarity report as To resubmit, meet, because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the decision to resubmit, meet, or turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled cannot support To resubmit, meet, versus Pause the program on this Pharma & Life Sciences Pharmacovigilance close, 505(b)(2) development lead must state the unresolved clinical or safety evidence requirement explicitly.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for 505(b)(2) development lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in biosimilar analytical similarity report that a second reviewer can re-perform